Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) - September 2007

International Angiology

Volumn 27, Issue 2, 2008, Pages 93-113

  Allegra, C ^a   Andreozzi, G M ^a   Antignani, P L ^a   Arosio, E ^a   Brevetti, G ^a   Cospite, M ^a   Del Guercio, R ^a   Deriu, G P ^a   Dzsinich, C ^a,a   Hussein, E ^a   Fernandes, J ^a   Fernandes, E ^a   Forconi, S ^a,a   Martini, R ^a   Novo, S ^a   Pagnan, A ^a   Poredos, P ^a   Rieger, H ^a   Roztocil, K ^a   Sosa, T ^a   Verlato, F ^a   Visona A ^a   Zamboni, P ^a   Cappelli, R ^a   Coccheri, S ^a   Jecu, A ^a   Minar, E ^a   Nicolaides, A W ^a   Prior, M ^a   Puchmayer, V ^a   Stvrtinova, V ^a   Szostek, M ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BUFLOMEDIL; CALCIUM ANTAGONIST; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESOGLYCAN; NAFTIDROFURYL; PENTOXIFYLLINE; PICOTAMIDE; PROPIONYLCARNITINE; RAMIPRIL; SULODEXIDE; TICLOPIDINE;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; CONFERENCE PAPER; CONSENSUS; DISEASE CLASSIFICATION; EUROPE; GENERAL PRACTITIONER; HUMAN; INTERMITTENT CLAUDICATION; ITALY; MEDICAL DOCUMENTATION; PATENT; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; SCREENING; SLOVENIA; TRAINING;

ASPIRIN; CAROTID STENOSIS; DISEASE PROGRESSION; EXERCISE TEST; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; LEG; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 44849110480     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (140)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-5.
2. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91:1472-9.
3. Selvin E, Erlinger TO. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
4. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tønnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J (Clin Res Ed) 1986;293:1137-40.
5. Rosenbloom MS, Flanigan DP, Schuler JJ, Meyer JP, Durham JR, Eldrup-Jorgensen J et al. Risk factors affecting the natural history of intermittent claudication. Arch Surg 1988;123:867-70.
6. O'Riordain DS, O'Donnell JA. Realistic expectations for the patient with intermittent claudication. Br J Surg 1991;78:861-3.
7. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
8. Brevetti G, Martone VD, Perna S, Cacciatore F, Corrado S, Di Donato A et al. Intermittent claudication and risk of cardiovascular events. Angiology 1998;49:843-8.
9. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al, Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
10. Hirsch AT, Hiatt WR, PARTNERS Steering Committee: PAD awareness, risk, and treatment: new resources for survival. The USA PARTNERS program. Vasc Med 2001;6:9-12.
11. Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta 1954;21:499-533.
12. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517-38. Erratum in: J Vasc Surg 2001;33:805.
13. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003;23:2131-7.
14. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
15. Arbustini E, Dal Bello B, Morbini P, Burke AP, Bocciarelli M, Specchia G et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 1999;82:269-72.
16. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
17. Fuster V, Fallon JT, Badimon JJ, Nemerson Y. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention. Thromb Haemost 1997;78:247-55.
18. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med 1998;3:231-9.
19. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001;134:224-38.
20. Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: its natural course. Surgery 1975;78:795-9.
21. Allister MC. The fate of patients with intermittent claudication managed non operatively. Am J Surg 1976;132:875-83.
22. Cronenwett JL, Warner KG, Zelenock GB, Whitehouse WM Jr, Graham LM, Lindenauer M et al. Intermittent claudication. Current results of nonoperative management. Arch Surg 1984;119:430-6.
23. Wilson SE, Schwartz I, Williams RA, Owens MI. Occlusion of the superficial femoral artery: what happens without operation? Am J Surg 1980;140:112-8.
24. Romano G, Corrado E, Muratori I, Novo G, Andolina G, Cospite V et al. Carotid and peripheral atherosclerosis in patients who underwent primary percutaneous coronary intervention and outcome associated with multifocal atherosclerosis. Int Angiol 2006;25:389-94.
25. Dormandy JA, Murray GD. The fate of the claudicant - a prospective study of 1969 claudicants. Eur J Vasc Surg 1991;5:131-3.
26. Andreozzi GM, Martini R. The fate of the claudicant limb. Eur Heart J 2002;4 Suppl B:B41-5.
27. Dormandy JA, Stock G, editors. Critical leg ischaemia, its pathophysiology and management. Berlin-Heidelberg: Springer-Verlag; 1990.
28. European Working Group on Critical Leg Ischaemia. Second European Consensus Document on Critical Leg Ischaemia. Circulation 1991;84 Suppl 4:1-26.
29. TASC Document - Management of Peripheral Arterial Disease (ThansAtlantic Inter-Society Consensus). Int Angiol 2000;19 Suppl 1:1-304.
30. Hirsch AT, Haskal ZJ, Hertzer NR. ACC/AHA Guidelines for the management of PAD. JACC 2006;20:1-75.
31. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG on behalf of the TASC II Working Group: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;1:1-75.
32. Novo G, Corrado E, Muratori I, Tantillo R, Bellia A, Galluzzo A et al. Markers of inflammation and prevalence of vascular disease in patients with metabolic syndrome. Int Angiol 2007;26:312-7.
33. AHA/NHLBI Scientific Statement: Diagnosis and management of the metabolic syndrome. Circulation 2005;112:2735-52.
34. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al.; REACH Registry Investigators: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
35. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21.
36. Osmundson PJ, Chesebro JH, O'Fallon WM, Zimmerman BR, Kazmier FJ, Palumbo PJ. A prospective study of peripheral occlusive arterial disease in diabetes. II. Vascular laboratory assessment. Mayo Clin Proc 1981;56:223-32.
37. Apelqvist J, Castenfors J, Larsson J, Stenström A, Agardh CD. Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer. Diabetes Care 1989;12:373-8.
38. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
39. Marek J, Mills JL, Harvich J, Cui H, Fujitani RM. Utility of routine carotid duplex screening in patients who have claudication. J Vasc Surg. 1996 Oct;24(4):572-7; discussion 577-9.
40. Pedrini L, Spartera C, Ponzio F, Arosio E, Andreozzi GM, Signorelli S et al. Definition of the diagnostic-therapeutic procedures in chronic peripheral obstructive arteriopathy Guidelines of the Italian Society for Angiology and Vascular Medicine (SIAPAV). Minerva Cardioangiol 2000;48:277-302.
41. Goessens BM, Visseren FL, Algra A, Banga JD, van dei Graaf Y (SMART Study Group): Screening for asymptomatic cardiovascular disease with noninvasive imaging in patients at high-risk and low-risk according to the European Guidelines on Cardiovascular Disease Prevention: the SMART study. J Vasc Surg 2006;43:525-32.
42. Mc Daniel MD, Cronenwett JL. Natural history of intermittent claudication. In: Porter JM, Taylor LM, editors. Basic data underlying clinical decision making in vascular surgery. St Louis; Quality Medical Publishing; 1994.p.129-33.
43. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation 1995;92:614-21.
44. Chaudhry H, Holland A, Dormandy J. Comparison of graded versus constant treadmill test protocols for quantifying intermittent claudication. Vasc Med 1997;2:93-7.
45. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-staged treadmill tests for the evaluation of claudication. Med Sci Sports Exerc 1991;23:402-8.
46. Cachovan M, Rogatti W, Woltering F, Creutzig A, Diehm C, Heidrich H et al. Randomized reliability study evaluating constant-load and graded-excercise treadmill test for intermittent claudication. Angiology 1999;50:193-200.
47. Montgomery PS, Gardner AW. The clinical utility of a 6-minute walk test in peripheral arterial occlusive disease patients. J Am Geriatr Soc 1998;46:706-11.
48. McDermott MM, Liu K, Guralnik JM, Martin GJ, Criqui MH, Greenland P. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg 1998;28:1072-81.
49. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol 1990;2:142-56
50. Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992;45:1101-9.
51. American Diabetes Association. Standards of medical care in Diabetes-2006. Diabetes Care 2006;29 Suppl 1:S4-S42.
52. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Medical management of peripheral arterial disease. J Thromb Haemost 2005;3:1628-37.
53. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
54. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39. Review. Erratum in: Circulation 2004;110:763.
55. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. Erratum in: 2000;342:1376. N Engl J Med 2000;342:748.
56. Farmer JA, Gotto AM Jr. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003;92 Suppl 1A:3-9i.
57. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y et al. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
58. Daskalopoulos SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005;12:443-52.
59. Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004;25:742-8.
60. O'Hare AM, Rodriguez RA, Bacchetti P. Low ankle brachial index associated with rise in creatinine level over time. Arch Intern Med 2005;165:1481-5.
61. Rashid ST, Salmon M, Agonwal S, Hamilton G, Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine. Eur J Endovasc Surg 2006;32:494-9.
62. O'Hare AM, Gidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency. Results from the National Health and Nutrition Examination Survey. 1999-2000. Circulation 2004;109:320-3.
63. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMI 2002;324:71-86.
64. Antignani PL. Treatment of chronic peripheral arterial disease). Curr Vasc Pharmacol 2003;1:205-16.
65. Ferguson JJ. The physiology of normal platelet function. In: Ferguson JJ, Chronos N, Harrington RA, editors. Anti-platelet therapy in clinical practice. London: Martin Dunitz; 2000.p.15-35.
66. Critical Leg Ischaemia Prevention Study (CLIPS) Group; Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007;261:276-84.
67. Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Hettiarachchi R, Marras E, Stefani PM, Girolami A, Büller HR. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost. 1999 May;81(5):715-22.
68. Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004;22:19-27.
69. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007;67:997-1026.
70. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-7.
71. Ceriello A, Motz E. Prevention of vascular events in diabetes mellitus: which "antithrombotic" therapy? Diabetologia 1996;39:1405-6
72. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005;83:148-58.
73. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. J Thromb Haemost. 2006;4:2566-8.
74. Neri Serneri GG, Coccheri S, Marubini E, Violi F; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004;25:1845-52.
75. Andreozzi GM, Visonà A, Parisi R, Arosio E (Angio-Veneto Working Group). Appropriateness of diagnostic and therapeutic pathways in patients with vascular disease. Minerva Cardioangiol 2007;55:397-424
76. Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999;159:337-45.
77. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication (Cochrane review). In: Cochrane Library, 3, 2002. Oxford: Update Software.
78. Wind J, Koelemay MJ. Exercise therapy and the additional effect of supervision on exercise therapy in patients with intermittent claudication. Systematic review of randomised controlled trials. Eur J Vasc Endovasc Surg 2007;34:1-9.
79. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602-9.
80. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 1994;90:1866-74.
81. Andreozzi GM, Signorelli S, Tornetta D. The rehabilitation in angiology. In: Strano A, Novo S, editors. Advances in vascular pathology. Amsterdam: Elsevier; 1990.p.591-7.
82. Gardner AW, Killewich LA, Montgomery PS, Katzel LI. Response to exercise rehabilitation in smoking and non-smoking patients with intermittent claudication. J Vasc Surg 2004;39:531-8.
83. Ubels FL, Links TP, Sluiter WJ, Reitsma WD, Smit AJ. Walking training for intermittent claudication in diabetes. Diabetes Care 1999;22:198-201.
84. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997;48:291-300.
85. Patterson RB, Pinto B, Marcus B, Colucci A, Braun T, Roberts M. Value of a supervised exercise program for the therapy of arterial claudication. J Vasc Surg 1997;25:312-8; discussion 318-9.
86. Savage P, Ricci MA, Lynn M, Gardner A, Knight S, Brochu M et al. Effects of home versus supervised exercise for patients with intermittent claudication. J Cardiopulm Rehabil 2001;21:152-7.
87. Gardner AW, Killewich LA, Montgomery PS, Katzel LI. Response to exercise rehabilitation in smoking and non-smoking patients with intermittent claudication. J Vasc Surg 2004;39:531-8.
88. Ohta T, Sugimoto I, Takeuchi N, Hosaka M, Ishibashi H. Indications for and limitations of exercise training in patients with intermittent claudication. Vasa 2002;31:23-7.
89. Manfredini F, Conconi F, Malagoni AM, Manfredini R, Basaglia N, Mascoli F et al. Training guided by pain threshold speed. Effects of a home-based program on claudication. Int Angiol 2004;23:379-87.
90. Manfredini F, Conconi F, Malagoni AM, Manfredini R, Mascoli F, Liboni A et al. Speed rather than distance: a novel graded treadmill test to assess claudication. Eur J Vasc Endovasc Surg 2004;28:303-9.
91. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsh AT. Exercise training for claudication. N Engl J Med 2002;347:1941-51.
92. Hickman P, Harrison DK, Hill A, McLaren M, Tamei H, MeCollum PT et al. Exercise in patients with intermittent claudication results in the generation of oxygen derived free radicals and endothelial damage. Adv Exp Med Biol 1994;361:565-70.
93. Brevetti G, Martone VD, de Cristofaro T, Corrado S, Silvestro A, Di Donato AM et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001;85:63-6.
94. Tisi PV, Shearman CP. The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking? Eur J Vasc Endovasc Surg 1998;15:7-17.
95. Cordova R, Martini R, D'Eri A, Salmistraro G, Mussap M, Plebani M et al. Flogistic arterial activity or own inflammatory attitude: what acts on PAD evolution? Int Angiol 2003;22:21-22.
96. Signorelli SS, Mazzarino MC, Di Pino L, Malaponte G, Porto C, Pennisi G et al. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 2003;8:15-9.
97. Andreozzi GM, Martini R, Cordova R, D'Eri A, Salmistraro G, Mussap M et al. Circulating levels of cytokines (IL-6 and IL-1beta), in patients with intermittent claudication, at rest, after maximal exercise treadmill test and during restore phase. Could they be progression markers of the disease? Int Angiol 2007;26:245-52.
98. Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Int Med 2002;252:448-55.
99. Andreozzi GM, Leone A, Martini R, Laudani R, Salmistraro G, Deinite G. Effectiveness and costs of a short-course supervised training program in claudicants. Proposal for a shared protocol with aerobic working load. Int Angiol. In press 2008.
100. Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil 2000;20:147-55.
101. Andreozzi GM. Terapia medica delle isehemie croniche degli arti inferiori. In: Benedetti Valentini F, editor. Chirurgia vascolare. Textbook della Società Italiana di Chirurgia Vascolare ed Endovascolare. Torino: Minerva Mediea; 2001.
102. o ed. Farmacologia clinica cardiovascolare. Padova: Piccin; 2000.p.569-98.
103. Lindgarde F, Jelnes R, Bjorkman H, Adielsson G, Kjellstrom T, Palmquist I et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989;80:1549-56.
104. Spengel F, Clément D, Boccalon H, Liard F, Brown T, Lehert P. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int Angiol 2002;21:20-7.
105. De Backer TL, Vander Stichele RH, Bogaert MG. Buflomedil for intermittent claudication. Cochrane Database Syst Rev 2001(1):CD000988.
106. Okuda Y, Kimura Y, Yamashita K. Cilostazol. Cardiovascular Drug Rev 1993;11:451-65.
107. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
108. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.
109. Brevetti G, Perna S, Sabbà C, Rossini A, Scotto di Uccio V, Berardi E et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992;13:251-5.
110. Angelini C, Lücke S, Cantarutti F. Carnitine deficiency of skeletal muscle: report of a treated case. Neurology 1976;26:633-7.
111. Engel AG. Possible causes and effects of carnitine deficiency in man. In: Frenkel RA, Mc Garry DJ, editors. Carnitine biosynthesis, metabolism and function. New York: Academic Press Inc.; 1980.p.271-84.
112. Tassani V, Cattapan F, Magnanimi L, Peschechera A. Anaplerotic effect of propionyl carnitine in rat heart mitochondria. Biochem Biophys Res Commun 1994;199:949-53.
113. Brevetti G, Angelini C, Rosa M, Carrozzo R, Perna S, Corsi M et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991;84:1490-5.
114. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992;73:346-53.
115. Brevetti G, Perna S, Sabbá C, Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995;26:1411-6.
116. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999;34:1618-24.
117. Hiatt WR. Carnitine and peripheral arterial disease. Ann N Y Acad Sci 2004;1033:92-8.
118. Andreozzi GM, Martini R, Cordova R, D'Eri A. L-propionylcarnitine protects tissues from ischaemic injury in an in vivo human ischaemia-reperfusion model. Clin Drug Invest 2002;22:16-21.
119. Andreozzi GM, Leone A, Laudani R, Martini R, Deinite G, Valentina Cataldi V. Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology. In press 2008.
120. Nenci G, Gresele P, Ferrari G, Santoro L, Gianese F. Tratment of intermittent claudication with mesoglycan. A placebo-controlled double-blind study. Thromb Haemost 2001;86:1181-7.
121. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V; Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J 2002;23:1057-65.
122. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006;113:2623-9.
123. Criqui MH, Browner D, Fronek A, Klauber MR, Barret-Connor E, Coughlin SS et al. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessels disease: an analysis of risk factors. Am J Epidemiol 1989;129:1110.
124. Ridker PM, Bassuk SS, Toth PP. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep 2003;5:341-9.
125. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 2003;108:166-70.
126. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study Circulation 2005;112:976-83.
127. Wilson SE, Schwartz I, Williams RA, Owens MI. Occlusion of the superficial femoral artery: what happens without operation? Am J Surg 1980;140:112-8.
128. Diehm C, Balzer K, Bisler H, Bulling B, Camci M, Creutzig A et al. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial. J Vasc Surg 1997;25:537-44.
129. Belch JJ, Bell PR, Creissen D, Dormandy JA, Kester RC, McCollum RD et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997;95:2298-302.
130. Belcaro G, Laurora G, Nicolaides AN, Agus G, Cesarone MR, DeSanctis MT et al. Treatment of severe intermittent claudication with PGE 1 - a short-term vs along-term infusion plan - a 20 week, European randomized trial: analysis of efficacy and costs. Angiology 1998;49:885-94; discussion 895.
131. Mohler ER 3rd, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003;41:1679-86.
132. Deriu G, Andreozzi GM, Grego F, Martini R. Indicazione alla rivascolarizzazione chirurgica, classica ed endovascolare, nel paziente con arteriopatia obliterante periferica. Minerva Cardioangiol 2001;49 Suppl 1:54-6.
133. Critical limb ischemia: management and outcome. Report of a national survey. The Vascular Surgical Society of Great Britain and Ireland. Eur J Vasc Endovasc Surg 1995;10:108-13.
134. Dormandy JA, Thomas PRS. What is the natural history of a critically ischaemic patient with and without his leg? In: Greenhalgh RM, Jamieson CW, Nicolaides AN, editors. Limb salvage and amputation for vascular disease. Philadelphia: WB Saunders; 1988.p.11-26.
135. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study U.K. Severe Limb Ischaemia Study Group. Eur J Vasc Surg 1991;5:511-6.
136. Martini R, Cordova R, Andreozzi GM on behalf of SIAPAV working Group on CLI. The intensive treatment of the unreconstructable critical limb ischaemia (CLI). Int Angiol 2003;22:1-2.
137. Dormandy JA, Supid R. The natural history of peripheral arterial disease. In: Tooke JE, Lowe GDO, editors. Text book of vascular medicine. London: Arnold ed.; 1996
138. Andreozzi GM. Flow dynamics and pathophysiological mechanisms of diseases of lower limbs arteries. In: Salmasi M, Strano A, editors. Angiology in practice. London: Kluwer Ed. 1996.p.251-70.
139. Andreozzi GM. Dynamic measurement and functional assessment of TcpO2 and TcpCO2 in the peripheral arterial disease. J Cardiovasc Diag Proc 1996;13:155-63:
140. Andreozzi GM, Martini R, Cordova RM, Busacca GC, D'Eri A. Could the severe claudication be classified in the critical leg ischaemia? Minerva Cardioangiol 2000;48:26-8.